Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the US market. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial. The launch is expected to expand access to quality and affordable treatment options for patients and healthcare providers.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer". The company announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan, a HER2-targeted antibody drug conjugate, for patients with platinum-resistant ovarian cancer.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the exchange about a U.S. FDA inspection at its manufacturing facility in Goa, India, which resulted in six observations, all of which are procedural in nature and none are repeat observations. The company does not anticipate any impact on the supply of its commercial products.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the schedule of an Analyst/Institutional Investor meeting to be conducted on June 30, 2026, in London.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.